Glucocorticoid-remediable Aldosteronism

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 2, 2011, Pages 333-341

  Halperin, Florencia ^a   Dluhy, Robert G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aldosterone; Glucocorticoid remediable aldosteronism; Hypertension

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANTIHYPERTENSIVE AGENT; CORTICOTROPIN; DEXAMETHASONE; DIURETIC AGENT; GLUCOCORTICOID; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; PREDNISONE; STEROID 11BETA MONOOXYGENASE;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BODY MASS; BODY SURFACE; CLINICAL FEATURE; CUSHING SYNDROME; EVENING DOSAGE; GENE DUPLICATION; GENETIC SCREENING; GEOGRAPHIC DISTRIBUTION; GLUCOCORTICOID REMEDIABLE ALDOSTERONISM; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; INHERITANCE; LOADING DRUG DOSE; MOLECULAR PATHOLOGY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SODIUM RESTRICTION; TREATMENT DURATION; ZONA FASCICULATA;

ADOLESCENT; ADULT; ALDOSTERONE SYNTHASE; CHILD; CHIMERISM; CHROMOSOMES, HUMAN, PAIR 8; CROSSING OVER, GENETIC; DEXAMETHASONE; GENE DUPLICATION; GENETIC TESTING; GLUCOCORTICOIDS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; PREVALENCE; RECEPTORS, MINERALOCORTICOID; STEROID 11-BETA-HYDROXYLASE;

EID: 79955724830     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.01.012     Document Type: Review

References (38)

1. Sutherland D.J., Ruse J.L., Laidlaw J.C. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966, 95(22):1109-1119.
2. Mulatero P., di Cella S.M., Williams T.A., et al. Glucocorticoid-remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab 2002, 87(7):3187-3191.
3. Lifton R.P., Dluhy R.G., Powers M., et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992, 2(1):66-74.
4. Pascoe L., Curnow K.M., Slutsker L., et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A 1992, 89(17):8327-8331.
5. Lifton R.P., Dluhy R.G., Powers M., et al. The molecular basis of glucocorticoid-remediable aldosteronism, a mendelian cause of human hypertension. Trans Assoc Am Physicians 1992, 105:64-71.
6. Jackson R.V., Lafferty A., Torpy D.J., et al. New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci 2002, 970:77-88.
7. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93(9):3266-3281.
8. Vonend O., Altenhenne C., Buchner N.J., et al. A German family with glucocorticoid-remediable aldosteronism. Nephrol Dial Transplant 2007, 22(4):1123-1130.
9. Jamieson A., Slutsker L., Inglis G., et al. Clinical, biochemical and genetic features of five extended kindred's with glucocorticoid-suppressible hyperaldosteronism. Endocr Res 1995, 21(1-2):463-469.
10. O'Mahony S., Burns A., Murnaghan D.J. Dexamethasone-suppressible hyperaldosteronism: a large new kindred. J Hum Hypertens 1989, 3(4):255-258.
11. Fallo F., Pilon C., Williams T.A., et al. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens 2004, 18(1):47-51.
12. Ding W., Liu L., Hu R., et al. Clinical and gene mutation studies on a Chinese pedigree with glucocorticoid-remediable aldosteronism. Chin Med J (Engl) 2002, 115(7):979-982.
13. Hsieh C.J., Wang P.W., Liu J.C., et al. Glucocorticoid-remediable aldosteronism: a case report. Changgeng Yi Xue Za Zhi 1997, 20(1):52-57.
14. Yokota K., Ogura T., Kishida M., et al. Japanese family with glucocorticoid-remediable aldosteronism diagnosed by long-polymerase chain reaction. Hypertens Res 2001, 24(5):589-594.
15. Carvajal C.A., Stehr C.B., Gonzalez P.A., et al. A de novo unequal cross-over mutation between CYP11B1 and CYP11B2 genes causes Familial Hyperaldosteronism type I. J Endocrinol Invest 2010, [Epub ahead of print].
16. Dluhy R.G., Anderson B., Harlin B., et al. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 2001, 138(5):715-720.
17. Stowasser M., Bachmann A.W., Huggard P.R., et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000, 85(6):2160-2166.
18. Rich G.M., Ulick S., Cook S., et al. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992, 116(10):813-820.
19. Dluhy R.G. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999, 84(12):4341-4344.
20. Stowasser M., Sharman J., Leano R., et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005, 90(9):5070-5076.
21. Joffe H.V., Adler G.K. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005, 10(1):31-37.
22. Litchfield W.R., Anderson B.F., Weiss R.J., et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998, 31(1 Pt 2):445-450.
23. Litchfield W.R., Coolidge C., Silva P., et al. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997, 82(5):1507-1510.
24. Simpson E.R., Waterman M.R. Regulation of the synthesis of steroidogenic enzymes in adrenal cortical cells by ACTH. Annu Rev Physiol 1988, 50:427-440.
25. Dluhy R.G., Lifton R.P. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995, 60(1):48-51.
26. Lifton R.P., Dluhy R.G., Powers M., et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355(6357):262-265.
27. Ganguly A., Grim C.E., Weinberger M.H. Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism. N Engl J Med 1981, 305(17):991-993.
28. Ulick S., Chan C.K., Gill J.R. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1990, 71(5):1151-1157.
29. Mosso L., Gomez-Sanchez C.E., Foecking M.F., et al. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives. Hypertension 2001, 38(3 Pt 2):688-691.
30. Gomez-Sanchez C.E., Montgomery M., Ganguly A., et al. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism. J Clin Endocrinol Metab 1984, 59(5):1022-1024.
31. Ulick S., Blumenfeld J.D., Atlas S.A., et al. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab 1993, 76(4):873-878.
32. Jonsson J.R., Klemm S.A., Tunny T.J., et al. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995, 207(2):565-571.
33. Dluhy R.G., Williams G.H. Glucocorticoid-remediable aldosteronism. Cardiovasc Res 1996, 31(6):870-872.
34. Jamieson A., Slutsker L., Inglis G.C., et al. Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. Clin Sci (Lond) 1995, 88(5):563-570.
35. Mulatero P., Veglio F., Pilon C., et al. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998, 83(7):2573-2575.
36. Stowasser M., Bachmann A.W., Jonsson J.R., et al. Clinical, biochemical and genetic approaches to the detection of familial hyperaldosteronism type I. J Hypertens 1995, 13(12 Pt 2):1610-1613.
37. Fardella C.E. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab 2001, 86(10):4805-4807.
38. Stowasser M., Bachmann A.W., Huggard P.R., et al. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000, 85(9):3313-3318.